ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
... IRVINE, Calif., July 29 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced it will release second quarter ...TA's website until September 5, 2009.
About
ista Pharmaceuticals
...
Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
... IRVINE, Calif., June 26 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ) today announced the Dermatologic and Ophthalmic ...., Ph.D., President and Chief Executive Officer of
ista Pharmaceuticals.
Although the FDA is not requ...
ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
... IRVINE, Calif., June 1 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced it has received notification fr...tion) on June 26, 2009.
On November 13, 2008,
ista announced it had filed its NDA with the FDA for Be...
DDL, Leader in Medical Device Package, Product and Material Testing, will be Presenting at This Year's MD&M Show in New York
...pe to learn from Levy include:
- An explanation of the most common methodologies being utilized by medical device manufacturers including ASTM and
ista procedures.
- An Analysis of the benefits and drawbacks of certain methodologies and valid alternative solutions.
- Detailed steps that need...
Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions
...tions, and mobile calibration facilities nationwide. Sypris Test & Measurement is ISO-9001:2000 registered, DSCC-approved and an ISO/IEC-17025 and
ista accredited company.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth ...
ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
...IRVINE, Calif., April 17 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced it will release first quarter 2...d on ISTA's website until June 7, 2009.
About
ista
...
ISTA Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
...IRVINE, Calif., March 10 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced it will present at the Cowen an...oftware download that may be necessary.
ABOUT
ista PHARMACEUTICALS
...
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
... IRVINE, Calif., Feb. 19 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today reported financial results for the quarte...% over the fourth quarter of 2007.
"In 2008,
ista became the fastest growing and fifth largest brand...
ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
... IRVINE, Calif., Feb. 12 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced it will release fourth quarter ...on ISTA's website until March 19, 2009.
About
ista Pharmaceuticals
...
ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
... IRVINE, Calif., Feb. 3 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced Vicente Anido, Jr., Ph.D., Pres...oftware download that may be necessary.
About
ista Pharmaceuticals
...
More>>
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
... IRVINE, Calif., June 8 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced positive results from a proof-o...., Ph.D., President and Chief Executive Officer of
ista Pharmaceuticals.
"ISTA is strongly committed ...
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
... LAUDERDALE, Fla., May 7 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today presented results from the Company's Bepr...e for at least 8 hours after dosing. In addition,
ista demonstrated Bepreve 1.5%, dosed twice daily for s...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
... IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced positive results from the Compa...., Ph.D., President and Chief Executive Officer of
ista Pharmaceuticals. "After reviewing the guidance fr...
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
... IRVINE, Calif., Jan. 15 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced that ISTA's New Drug Applicatio...d market bepotastine for ophthalmic use. In 2006,
ista licensed the exclusive North American rights from ...
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
... IRVINE, Calif., Dec. 4 /PRNewswire-FirstCall/ --
ista Pharmaceuticals, Inc. (Nasdaq:
ista ), an ophthalmic pharmaceutical company, today ann... marketed Xibrom twice-daily formulation.
ista has discussed the data with the FDA and plans to p...
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
...FirstCall/ -- ISTA
Pharmaceuticals, Inc. (Nasdaq:
ista ), today announced positive results from
the preli...ced May 8, 2007, which used
the same study design.
ista currently is analyzing the results of an ocular
sa...ompany
completes its analysis of the full dataset,
ista expects to file a New Drug
Application (NDA) with ...
Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
...he extended topical administration of bromfenac.
ista Pharmaceuticals (Nasdaq:
ista ) supported Dr. Grant's study with an
unrestricted...be confirmed through clinical studies, and, should
ista decide to
pursue a potential label change,...
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
...FirstCall/ -- ISTA
Pharmaceuticals, Inc. (Nasdaq:
ista ), today reported topline results of a
clinical tr...n be
administered once-daily."
Conference Call
ista will host a conference call with a simultaneous we...in Japan in
2000 by Senju Pharmaceuticals Co. Ltd.
ista acquired U.S. marketing rights
for Xibrom in 2002 ...
ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
... IRVINE, Calif., Feb. 22 /PRNewswire-FirstCall/ --
ista Pharmaceuticals,
Inc. (Nasdaq:
ista ), announced today the acceptance of an abstract
d...s supported by an
unrestricted research grant from
ista Pharmaceuticals. The full abstract is
available at...
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
... IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ --
ista Pharmaceuticals,
Inc. (Nasdaq:
ista ), presented today results from the Company's two ...ology (AAO) being held in New Orleans, Louisiana.
ista also announced today a second poster presentation ...
More>>